Analytical interference with most current commercial HIV molecular assays in patients treated by idecabtagene vicleucel, a recently approved lentivirus-based chimeric antigen receptor T-cell therapy

We report the case of a 65-year-old woman followed for multiple myeloma diagnosed in 2007. After multiple lines of therapy and relapses, she received idecabtagene vicleucel (a lentiviral-based vector chimeric antigen receptor [CAR] T-cell immunotherapy). At day 9 after infusion, HIV-1, HBV and HCV molecular testing were irrelevantly prescribed by the clinician, without any particular reason justifying them. A positive HIV-1 signal was detected by two commercial RT-PCR assays (Alinity m HIV-1, Abbott; 2.8 log cp/mL and Xpert HIV-1 Viral Load XC, Cepheid; 3.3 log cp/mL).